永安药业：拟收购控股子公司凌安科技少数股东股权

Core Viewpoint - The company plans to acquire 49.2% equity of Hubei Ling'an Technology Co., Ltd. from minority shareholders for 27 million yuan, aiming to achieve 100% ownership and enhance control over the subsidiary [1] Group 1: Acquisition Details - The acquisition involves minority shareholders Zhang Yong, Xia Changpei, and Dai Liang [1] - After the acquisition, the company will hold 100% equity of Ling'an Technology [1] Group 2: Business Transformation - Ling'an Technology successfully completed its business transformation in the first half of this year [1] - The company is now engaged in the production of monohydrate creatine, which is a key business segment for the company [1] Group 3: Strategic Objectives - The acquisition aims to strengthen the company's control over Ling'an Technology [1] - It is intended to reduce management costs and control risks [1] - The move is expected to accelerate Ling'an Technology's business expansion and market layout in the monohydrate creatine sector [1]